Moderna, Inc. (MRNA)
| Market Cap | 14.22B |
| Revenue (ttm) | 5.08B |
| Net Income (ttm) | -2.22B |
| Shares Out | 384.82M |
| EPS (ttm) | -5.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,279,167 |
| Open | 37.29 |
| Previous Close | 37.29 |
| Day's Range | 36.41 - 38.22 |
| 52-Week Range | 35.80 - 170.47 |
| Beta | 1.69 |
| Analysts | Hold |
| Price Target | 83.00 (+124.69%) |
| Earnings Date | Nov 7, 2024 |
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vac... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $83.0, which is an increase of 124.69% from the latest price.
News
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
Cramer's Mad Dash: Moderna gets upgrade from HSBC
CNBC's Jim Cramer reports on the latest news regarding Moderna.
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...
Moderna, Inc. (MRNA) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
Moderna, Inc. (NASDAQ:MRNA) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 10:00 AM ET Company Participants Stephen Hoge - President Conference Call Participants Evan Wang ...
The Score: Spirit, Tesla, Moderna and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news.
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Hu...
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme...
Vaccine maker stocks fall after conspiracy theory-spreading RFK Jr. tapped to lead health department
Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively.
Pharma shares hit as Trump picks RFK Jr to lead health department
Choice of vaccine critic knocks some of world's biggest drugmakers including Moderna, AstraZeneca and GSK
Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head
Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that President-elect Donald Trump would select va...
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U....
Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS
Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Servic...
Moderna, Inc. (MRNA) UBS Global Healthcare Conference (Transcript)
Moderna, Inc. (NASDAQ:MRNA) UBS Global Healthcare Conference November 13, 2024 6:30 PM ET Company Participants Jamey Mock - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Eli...
PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax's Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government's Project NextGen
MUMBAI, India & HYDERABAD, India--(BUSINESS WIRE)-- #COVID19--NIH NIAID will conduct and sponsor the Phase I clinical trial for a computationally-designed mRNA COVID-19 vaccine developed by Indian bio...
Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers
EMERYVILLE, Calif.--(BUSINESS WIRE)--CRDMO capabilities are tailored for a full range of mRNA applications, including small-scale quantities for personalized cancer vaccines (PCVs).
Poster Presentation at International mRNA Health Conference Showcases Clinical Evidence that PharmaJet® Delivery Systems Enable mRNA Vaccine Delivery
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet needle-free technology enhances mRNA vaccine immune response and has been successfully adopted into multiple vaccine development programs.
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Comp...
mRNA Synthesis & Manufacturing Market - Global Forecast to 2029
Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis...
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
On Thursday, Moderna Inc. MRNA reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion.
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna has received approval from Canada's health regulator for its respiratory syncytial virus vaccine in adults 60 years of age and older, the vaccine maker said on Friday.
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeu...
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA fol...
Moderna Stock Rises on Surprise Q3 Profit
Moderna (MRNA) reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs.
Moderna (MRNA) Q3 2024 Earnings Call Transcript
Call Start: 08:00 January 1, 0000 9:00 AM ET Moderna Inc. (NASDAQ:MRNA) Q3 2024 Earnings Conference Call November 7, 2024 8:00 am ET Company Participants Stéphane Bancel - Chief Executive Officer Ste...
2025 will be 'fairly challenging' for Moderna: Analyst
Moderna (MRNA) shares are getting a boost in Thursday's pre-market trading as the pharmaceutical giant reported an unexpected profit in its third quarter. The company posted $1.86 billion in revenue a...